Saluggia - December 16, 2019 - DiaSorin (FTSE MIB: DIA) announced today that it has received FDA clearance for its Simplexa VZV Swab Direct assay.

The CLIA moderate-complexity assay is designed for use on the LIAISON MDX instrument to quickly and accurately detect varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens.

DiaSorin also attained CE Marketing for the assay in September. This assay complements the company's Simplexa VZV Direct kit, which is for use with CSF samples.

Varicella-zoster virus infection causes two clinically distinct forms of disease, a primary infection (chickenpox) or a secondary infection (shingles). Although vaccines have been around since the 1990s, it is estimated that 90% of the population will acquire the diseases by the age of 15. These infections can affect different areas of the body including the skin, genitals, nasal cavities, and the eyes and can cause severe long-term disability or disfigurement depending on the affected site and treatment.

It is not always possible to visually distinguish VZV lesions from HSV lesions, as the clinical presentation can be similar. This makes it critical for labs to identify VZV infection for proper patient treatment and management.

Carlo Rosa, CEO of DiaSorin Group, commented: "With this release, we now offer a comprehensive menu of VZV and HSV tests from cerebral spinal fluid, mucocutaneous swab specimens, and cutaneous swab specimens. Customers can also run these tests at the same time using the same disc. We are dedicated to providing products that streamline testing workflows and improve patient management."

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:
Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel. +39.0161.487988
riccardo.fava@diasorin.it